Drug intelligence / Profile preview

glucose-salt solution

Development stage: Preclinical
Administration: Intraperitoneal

Overview

A solution containing glucose and various salts, designed to be added to intraperitoneal fluid during peritoneal dialysis. Its primary function is to maintain a stable intraperitoneal osmolarity, compensate for glucose uptake and dilution, and thereby enhance ultrafiltration, aiding in the removal of toxins and excess fluid from patients with end-stage renal disease.

Targets

SLC5A1 (Sodium Glucose Cotransporter 1)

Beyond the preview

Go deeper on glucose-salt solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glucose-salt solution.

Explore the full profile